ESMO World Congress on Gastrointestinal Cancer | Conference

Dr. Peeters on the Frequency of S492R Mutations Following EGFR Inhibition in mCRC

June 27th 2014

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the frequency of S492R mutations found in patients with metastatic colorectal cancer patients who were treated with panitumumab or cetuximab monotherapy.

Dr. Tabernero on Sequencing Angiogenesis Inhibitors in mCRC

June 27th 2014

Josep Tabernero, MD, PhD, head, Medical Oncology Department, Vall d'Hebron University Hospital, director, Vall d'Hebron Institute of Oncology, discusses his opinions on which patients with metastatic colorectal cancer should receive aflibercept following bevacizumab.

Ruxolitinib Combo Improves Outcomes in Metastatic Pancreatic Cancer

June 26th 2014

Adding ruxolitinib to capecitabine as a second-line treatment for patients with metastatic pancreatic cancer significantly improved survival for a subgroup with a high degree of local and systemic inflammation compared with capecitabine plus placebo.

Adding Cetuximab to Chemoradiation in Non-operable Esophageal Cancer Does Not Improve Survival

June 26th 2014

Adding cetuximab to concurrent chemoradiotherapy did not improve overall survival in patients with adenocarcinoma or squamous cell carcinoma of the esophagus

Prognostic Scale Developed for Overall Survival in Locally Advanced Pancreatic Cancer

June 26th 2014

Four independent prognostic factors for improved overall survival in patients with locally advanced pancreatic cancer emerged from an analysis of the LAP 07 phase III trial.

Dr. O'Reilly on Nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX in Pancreatic Cancer

June 25th 2014

Eileen M. O'Reilly, MD, associate director, David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, discusses using nab-paclitaxel plus gemcitabine versus FOLFIRINOX as treatment for patients with untreated metastatic pancreatic cancer.

Dr. Tempero Discusses Hereditary Pancreatic Cancer

June 25th 2014

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the two main types of hereditary pancreatic cancer.

Dr. Marc Peeters on the Aflibercept Toxicity Profile

July 9th 2013

Marc Peeters, MD, PhD, from the Antwerp University Hospital, discusses the importance of properly managing the toxicities associated with aflibercept when treating patients with metastatic colorectal cancer.

IV Calcium/Magnesium Has No Effect on Oxaliplatin-Induced Neuropathy

July 6th 2013

Intravenous calcium plus magnesium given before or after adjuvant FOLFOX chemotherapy has absolutely no effect on the development of sensory neurotoxicity induced by oxaliplatin.

Dr. Lenz Explores KRAS/NRAS Mutations in Colorectal Cancer

July 6th 2013

Heinz-Josef Lenz, MD, from the USC Norris Comprehensive Cancer Center, discusses the potential predictive impact of KRAS and NRAS mutations in metastatic colorectal cancer.

Simple, Inexpensive Blood Test Poised to Be a Real "Game Changer" in CRC Screening

July 6th 2013

A simple and inexpensive blood test is being developed that can be used to screen patients for premalignant colorectal cancer lesions which, once perfected, will be a real game changer.

Better Responders in VELOUR Derive Enhanced Benefit From Aflibercept

July 6th 2013

Better responders within a cohort of patients from the VELOUR study derive enhanced benefit from aflibercept when combined with FOLFIRI, a post-hoc analysis of the study shows.

Novel VEGFR-2 Inhibitor Prolongs Survival in Advanced Gastric/GEJ Adenocarcinoma

July 5th 2013

Ramucirumab significantly prolongs survival in patients with advanced gastric or gastroesophageal junction adenocarcinoma following progression on first-line therapy.

Dr. Ruff on Selecting Anti- Angiogenic Agents in mCRC

July 5th 2013

Paul Ruff, MD, from the University of Witwatersrand, Johannesburg, South Africa, elaborates on factors that can be utilized to select an appropriate antiangiogenic therapy as a second-line treatment in metastatic colorectal cancer.

Nab-paclitaxel Plus Gemcitabine a Strong Predictor of Survival in Metastatic Pancreatic Cancer

July 4th 2013

Treatment with weekly nab-paclitaxel plus gemcitabine remains a strong independent predictor of both OS and PFS in patients with metastatic pancreatic cancer compared with gemcitabine alone.

Gemcitabine Response Depends on Gene Expression in Patients With Pancreatic Cancer

July 4th 2013

Patients who express low levels of a critical gene involved in transporting gemcitabine into pancreatic tumor cells have virtually no overall survival advantage from treatment with the drug in the adjuvant setting.

Dr. Venook on Geographic Variations in Treatments

July 4th 2013

Alan P. Venook, MD, from the University of California, San Francisco, describes factors that contribute to the geographic variations seen in therapies utilized to treat cancer in the United States and Europe.